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Abstract
Recent reports of mild to severe influenza-like illness in humans caused by a novel swine-origin
2009 A(H1N1) influenza virus underscore the need to better understand the pathogenesis and
transmission of these viruses in mammals. Here, selected 2009 A(H1N1) isolates were assessed for
their ability to cause disease in mice and ferrets, and compared with a contemporary seasonal H1N1
virus for their ability to transmit by respiratory droplets to naïve ferrets. In contrast to seasonal
influenza H1N1 virus, 2009 A(H1N1) viruses caused increased morbidity, replicated to higher titers
in lung tissue and were recovered from the intestinal tract of intranasally inoculated ferrets. The 2009
A(H1N1) viruses exhibited less efficient respiratory droplet transmission in ferrets in comparison to
the high-transmissible phenotype of a seasonal H1N1 virus. Transmission of the 2009 A(H1N1)
viruses was further corroborated by characterizing the binding specificity of the viral hemagglutinin
to the sialylated glycan receptors (in the human host) using dose-dependent direct receptor binding
and human lung tissue binding assays.
On June 11, 2009 the World Health Organization raised the global pandemic alert level to
phase 6, the pandemic phase, in response to the emergence and global spread of a novel
influenza A (H1N1) virus containing a unique combination of genes of swine origin (1).
Leading up to this event were reports of increased numbers of patients with influenza-like
illness and associated hospitalizations and deaths in several areas of Mexico during March and
April (2). On April 15 and 17, 2009, two unrelated cases of febrile respiratory illness in children
who resided in adjacent counties in southern California were confirmed to be caused by
infection with a swine-origin influenza A (H1N1) virus (3,4), hereafter referred to as 2009 A
(H1N1) viruses. In the period March-June 21, 2009, there have been over 44,000 laboratory-
confirmed human cases of influenza 2009 A(H1N1) infections reported in 85 countries on 6
continents (5). Although most confirmed cases have occurred among individuals with
uncomplicated, febrile, upper respiratory tract illnesses with symptoms similar to seasonal
influenza, there have been over 180 deaths and approximately 40% of infected individuals have
experienced symptoms that include gastrointestinal distress and vomiting, which is higher than
that reported for seasonal influenza (6). The current case fatality rate of this global outbreak is
uncertain as is the total number of persons infected with the 2009 A(H1N1) virus (7).
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The factors that lead to the generation of pandemic viruses are complex and poorly understood,
however the ability of a novel influenza virus to cause significant illness and transmit through
the air are critical properties of pandemic influenza strains (8–10). Thus, knowing the inherent
virulence and transmissibility of the 2009 A(H1N1) viruses, relative to seasonal influenza
viruses, is important for executing appropriate public health responses.
We have therefore characterized the pathogenesis and transmissibility three 2009 A(H1N1)
viruses (isolated from nasopharyngeal swabs) in the ferret (Mustela putorius furo) model,
which appears to recapitulate not only human disease severity but also efficient transmission
of seasonal (H1N1 and H3N2) influenza viruses and the poor transmission of avian (H5 and
H7) influenza viruses (11–14). A/California/04/2009 (CA/04) virus was isolated from a
pediatric patient with uncomplicated, upper respiratory tract illness; A/Mexico/4482/2009
(MX/4482) virus was isolated from a 29-year-old female patient with severe respiratory
disease; and Texas/15/2009 (TX/15) virus was isolated from a pediatric patient with fatal
respiratory illness. The three 2009 A(H1N1) viruses were compared with a representative
seasonal H1N1 virus, A/Brisbane/59/2007 (Brisbane/07; H1N1) (14). To date, 2009 A(H1N1)
viruses exhibit high genome sequence identity (99.9%) and lack previously identified
molecular markers of influenza A virus virulence or transmissibility (1). Alignments of the
deduced amino acid sequences between the three viruses we studied revealed a few differences.
These were observed in the hemagglutinin (HA), neuraminidase (NA), polymerase (PA),
nucleoprotein (NP), and non-structural proteins NS1 and NS2 (Supplementary Table 1).
Viruses were propagated in Madin-Darby canine kidney cells (MDCK) or embroynated hens’
eggs (15).
For respiratory droplet transmission experiments, three ferrets were inoculated intranasally
(i.n.) with 106 PFU (plaque forming units) of virus (15). Approximately 24 hours later,
inoculated-contact animal pairs were established by placing a naïve ferret in each of three
adjacent cages with perforated side walls, allowing exchange of respiratory droplets without
direct or indirect contact (11). Direct contact transmission experiments were performed
similarly except naïve ferrets were placed in the same cage as each of the inoculated ferrets
where they shared a common food and water source. Inoculated and contact animals were
monitored for clinical signs over a 14 day period. Transmission was assessed by titration of
infectious virus in nasal washes and detection of virus specific antibodies in convalescent sera
(11). Three additional inoculated ferrets from each virus-infected group were euthanatized on
day 3 post-inoculation (p.i.) for assessment of infectious virus in tissues (15).
Ferrets inoculated with CA/04 virus showed no overt clinical signs but displayed mild signs
of inactivity (relative inactivity index, RII = 1.0). TX/15 or MX/4482 virus infection resulted
in more pronounced clinical features including a slight increase in RII (1.2). Significantly
greater weight loss was observed with all of the 2009 A(H1N1) viruses than with the seasonal
influenza virus, Brisbane/07 (P<0.05; Table 1). One ferret infected by direct contact
transmission from a TX/15-inoculated ferret was euthanatized at 10 days p.i. due to excessive
weight loss and three of six MX/4482-inoculated ferrets were euthanatized before the end of
the experimental period due to severe lethargy or excessive weight loss (Table 1). Ferrets
inoculated with any of the 2009 A(H1N1) virus isolates shed high peak mean titers of infectious
virus in nasal washes as early as day 1 p.i (107.1–7.7 PFU/ml) (Supplementary Figures 1 & 2),
that were sustained at titers of ≥104.4 PFU/ml for 5 days p.i. The 2009 A(H1N1) virus shedding
showed similar kinetics to Brisbane/07 virus, which was also sustained for 5 days in ferrets at
titers of ≥104.7 PFU/ml. In contrast to Brisbane/07, CA/04, TX/15 and MX/4482 viruses were
detected in the lower respiratory tract at high titers (105.8–6.0 PFU/g lung tissue) and the
intestinal tract. For the latter, viral titers were detected in rectal swabs or tissue samples
collected throughout the intestinal tract (Table 1, Supplementary Figure 3). There was no
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evidence of viremia or infectious virus in the brain, kidney, liver and spleen tissues with any
of the viruses tested (Supplementary Figure 3).
Consistent with the experimental transmission data obtained with contemporary human H1N1
and H3N2 viruses (11,14,17), the seasonal influenza H1N1 (Brisbane/07) virus efficiently
transmitted via direct contact and respiratory droplets to all of the contact ferrets which shed
virus as early as day 1 post-contact (p.c.) (Supplementary Figures 1 & 2). Direct contact
transmission was observed between all animal pairs for CA/04, TX/15 and MX/4482 viruses;
infectious virus was recovered from nasal washes and seroconversion was detected in all
contact animals (Table 1,Supplementary Figure 1). However, the 2009 A(H1N1) viruses did
not spread by respiratory droplet to every contact ferret and transmission was delayed by five
or more days post exposure in two of six infected ferret pairs (Supplementary Figure 2).
Respiratory droplet transmission of 2009 A(H1N1) viruses was significantly reduced
compared to respiratory droplet transmission of the seasonal influenza virus (P≤0.01; Table
1). Sneezing was frequently observed in Brisbane/07-inoculated ferrets but was rarely observed
in the CA/04-, TX/15- or MX4482-inoculated ferrets during the study period, similar to the
infrequent sneezing observed in ferrets infected with avian influenza viruses (11). Collectively,
these findings demonstrate that 2009 A(H1N1) viruses elicited elevated respiratory disease
relative to seasonal H1N1 viruses in ferrets, yet despite efficient direct contact transmission,
the viruses exhibited less efficient respiratory droplet transmission, compared with
contemporary seasonal human influenza viruses (11,14).
The binding of influenza viruses to their target cells is mediated by viral HA and binding
preference to specific sialylated glycan receptors is a critical determinant of H1N1 virus
transmission efficiency in ferrets (14,17,18). We examined the glycan binding properties of
the 2009 A(H1N1) HA by dose-dependent direct receptor binding (18) and human lung tissue
binding assays using recombinantly expressed soluble CA/04 HA (19). In the direct glycan
receptor binding assay, CA/04 HA exhibited a dose-dependent binding to only a single α2–6
glycan (6’SLN-LN) and only minimal binding to α2–3 glycans (Figure 1). Although the
binding pattern of CA/04 HA is similar to that of HA from the 1918 pandemic influenza A
virus (A/South Carolina/1/1918 or SC18), the binding affinity of CA/04 HA is considerably
lower than that of SC18 HA (Supplementary Figures 4 & 5). Examining the tissue binding of
CA/04 HA indicates that it binds uniformly to the apical surface of the human tracheal
(representative upper respiratory) tissue sections (Figure 2). This binding pattern correlates
with the predominant distribution of α2–6 sialylated glycans on the apical surface of the
tracheal tissue (19) and the α2–6 binding of CA/04 HA in the direct binding assay. Although
CA/04 shows some binding to alveolus, it is not as extensive as the tracheal binding consistent
with the minimal α2–3 binding observed in the direct binding assay.
The receptor-binding site (RBS) of the 2009 A (H1N1) HAs (20), used in this study, were
compared to those from SC18 and the recent seasonal influenza H1N1 viruses (Table 2). The
similarity in the binding pattern between CA/04 HA and SC18 HA could potentially arise from
the majority of the ”similar or analogous” RBS residues between these HAs including Asp190
and Asp225, which are ‘hallmark’ amino acids of human adapted H1N1 HAs that make optimal
contacts with the α2–6 glycans. The main differences in RBS between SC18 and CA/04 HA
are at positions 145, 186, 189, 219 and 227. The CA/04 HA has a unique Lys145 which provides
an additional anchoring contact for the sialic acid (20). The residues at 186, 187, 189 are
positioned to form an interaction network with Asp190 (18,20). In the case of SC18 HA, this
network involves oxygen atoms of Thr187, Thr189 and Asp190 (18). In a similar fashion, in
the case of CA/04 HA, this network could potentially be formed by the oxygen atoms of Ser186,
Thr187 and Asp190. The residues 219 and 227 in turn influence the orientation of residue 186.
Comparison of residues 219 and 227 (Table 2) reveals that either both amino acids are
hydrophobic such as Ala219 and Ala227 (as observed in SC18 HA) or they are charged residues
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such as Lys219 and Glu227 (as observed in the seasonal influenza HAs). Interestingly, the
2009 A(H1N1) HAs have a unique combination of Ile219 and Glu227 that results in a set of
interactions that is neither fully hydrophobic nor fully charged. This combination could
destabilize the hydrophobic or ionic network of residues at 186, 219 and 227 thereby disrupting
optimal contacts with the α2–6 sialylated glycans (Figure 3). Analysis of the RBS of the 2009
A(H1N1) HA offers an explanation for the lower α2–6 binding affinity of CA/04 HA as
compared to SC18 HA despite the similar binding pattern (Supplementary Figure 4). Taken
together, the differences in the glycan binding property of the 2009 A(H1N1) HA when
compared to that of SC18 and the recent seasonal influenza HAs correlate with the observed
differences in the respiratory droplet transmission in ferrets.
To evaluate the pathogenicity of the novel H1N1 viruses in another mammalian species, we
inoculated BALB/c mice i.n. with three 2009 A(H1N1) isolates and then determined virus
replication, morbidity (as measured by weight loss), 50% mouse infectious dose (MID50) and
50% lethal dose (LD50) titers. In addition to CA/04 and TX/15, A/Mexico/4108/2009 (Mex/
4108; H1N1) virus, obtained from hospitalized case of non-fatal infection, was included in the
mouse pathotyping experiments. The 2009 A(H1N1) viruses isolates did not kill mice (LD50
>106 PFU or EID50), which displayed only transient weight reduction (Table 3), however, all
three 2009 A(H1N1) viruses replicated efficiently in mouse lungs without prior host adaptation
(Table 3). Typically, human influenza A strains of the H1N1 subtype replicate efficiently in
mice only after they are adapted to growth in these animals (21). The MID50 titers, determined
by the detection of virus in the lungs of mice 3 days p.i., were markedly low (MID50 =
100.5–1.5 PFU or EID50), indicating high infectivity in this model. We next determined whether
2009 A(H1N1) viruses replicated systemically in the mouse after intranasal infection, a
characteristic of virulent avian influenza (H5N1) viruses isolated from humans, but not 1918
(H1N1) virus (17,22). All mice infected with CA/04, Tx/15, or Mex/4108 viruses had
undetectable levels (<10 PFU/ml) of virus in whole spleen, thymus, brain and intestinal tissues,
indicating that the 2009 A(H1N1) viruses did not spread to extrapulmonary organs in the
mouse.
The full clinical spectrum of disease caused by 2009 A(H1N1) viruses and its transmissibility
are not completely understood. The present study shows that overall morbidity and lung viral
titers were higher in ferrets infected with 2009 A(H1N1) isolates compared with the seasonal
H1N1 virus. Moreover, the detection of 2009 A(H1N1) viruses in the intestinal tissue of ferrets
is consistent with gastro-intestinal involvement among some human 2009 A(H1N1) cases
(6). Although the 2009 A(H1N1) viruses demonstrated similar replication kinetics as the
seasonal H1N1 virus in the upper respiratory tract of inoculated ferrets, the 2009 A(H1N1)
viruses did not spread to all naïve ferrets by respiratory droplets. This lack of efficient
respiratory droplet transmission suggests that additional virus adaptation in mammals may be
required to reach the high-transmissible phenotypes observed with seasonal H1N1 or the 1918
pandemic virus (14,17).
It was demonstrated previously that the efficiency of respiratory droplet transmission in ferrets
correlates with the α2–6 binding affinity of the viral HA (17). Only a single amino acid mutation
in HA of the high-transmissible SC18 virus led to a virus (NY18) that transmitted inefficiently
and the α2–6 binding affinity of NY18 HA was substantially lower than that of SC18 HA
(Supplementary Figure 5). In a similar fashion the substantially lower α2–6 binding affinity of
CA/04 HA to that of NY18 HA correlates with the less efficient 2009 A(H1N1) respiratory
droplet transmission (Supplementary Figure 5).
Adaptation of the polymerase basic protein 2 (PB2) is also critical for efficient aerosolized
respiratory transmission of an H1N1 influenza virus (14,17,23). A single amino acid
substitution from glutamic acid to lysine at amino acid position 627 supports efficient influenza
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virus replication at the lower temperature (33°C) found in the mammalian airway, and
contributes to efficient transmission in mammals (14,23). All three of the 20th century influenza
pandemics were caused by viruses containing human adapted PB2 genes and, in general, lysine
is present at position 627 among the human influenza viruses whereas a glutamic acid is found
in this position among the avian influenza isolates that fail to transmit efficiently among ferrets
(14). In contrast to Brisbane/07 virus and other seasonal H1N1 viruses, all 2009 A(H1N1)
viruses to date with an avian influenza lineage PB2 gene possess a glutamic acid at residue
627 (1). The phenotype of PB2 is determined by the amino acid at position 627, which can
arise by mutant selection or reassortment, and along with adaptive changes in the RBS should
be closely monitored as markers for enhanced virus transmission.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dose dependent direct receptor binding of CA/04 HA
A streptavidin plate array comprising representative biotinylated α2–3 and α2–6 sialylated
glycans were used for the assay. The biotinylated glycans include 3’SLN, 6’SLN, 3’SLN-LN,
6’SLN-LN and 3’SLN-LN-LN. LN corresponds to lactosamine (Galβ1–4GlcNAc) and 3’SLN
and 6’SLN respectively correspond to Neu5Ac α2–3 and Neu5Ac α2–6 linked to LN. The
assay was carried out as described previously (18) for an entire range of HA concentration
from 0.01 – 40 µg/ml by pre-complexing HA: primary antibody: secondary antibody in the
ratio 4:2:1 to enhance the multivalent presentation of HA. The binding signals for HA
concentrations below 1 µg/ml were at background level and hence there concentrations are not
shown on the x-axis. The y-axis shows the normalized binding signal as a percentage of the
maximum value.
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Figure 2. Human tissue binding of CA/04 HA
Shown in the top is the binding of CA/04 HA at 20 µg/ml concentration to apical surface
(white arrow) of human tracheal tissue sections (green as against propidium iodide staining in
red). The binding of the recombinantly expressed HA to the human tissues was carried out as
described previously (19) by precomplexing HA: primary antibody:secondary antibody in the
ratio 4:2:1 to enhance multivalent presentation of HA. Note the binding of HA to the apical
surface of tracheal tissue which is known to predominantly express α2–6 sialylated glycans
(19). Shown in the bottom is the minimal binding of HA at 20 µg/ml concentration to the
alveolar tissue section. The sialic acid specific binding of HA to the tracheal tissue section was
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confirmed by blocking of HA binding to the tissue section pre-treated with 0.2 U of Sialidase
A (recombinantly expressed in Arthrobacter ureafaciens).
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Figure 3. Structural model of CA/04 HA bound to α2–6 oligosaccharide
The contacts of CA/04 HA with an α2–6 oligosaccharide (Neu5Ac α2–6Galβ1–4GlcNAcβ1–
3Galβ1–4Glc) were analyzed by constructing a structural model as described previously (20).
Shown in the figure is the cartoon representation of the glycan binding site of CA/04 HA where
the side chains of the key amino acids are shown in stick representation (colored by atom
carbon: gray; oxygen: red; nitrogen:blue). The α2–6 oligosaccharide is shown as a stick
representation (colored by atom carbon: green; oxygen: red; nitrogen:blue) and labeled blue
starting from non-reducing end Neu5Ac-1 to reducing end Glc-5. The potential destabilization
of the interaction network due to the Ile219/Glu227 combination is highlighted in red dotted
circle.
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